BR112022025220A2 - Composição farmacêutica e artigo farmacêutico - Google Patents

Composição farmacêutica e artigo farmacêutico

Info

Publication number
BR112022025220A2
BR112022025220A2 BR112022025220A BR112022025220A BR112022025220A2 BR 112022025220 A2 BR112022025220 A2 BR 112022025220A2 BR 112022025220 A BR112022025220 A BR 112022025220A BR 112022025220 A BR112022025220 A BR 112022025220A BR 112022025220 A2 BR112022025220 A2 BR 112022025220A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
dosage forms
article
compositions
enterocin
Prior art date
Application number
BR112022025220A
Other languages
English (en)
Inventor
Bolz Steffen-Sebastian
Deusch Kai
Original Assignee
Aphaia Ip Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphaia Ip Ag filed Critical Aphaia Ip Ag
Publication of BR112022025220A2 publication Critical patent/BR112022025220A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA E ARTIGO FARMACÊUTICO. A presente invenção refere-se a composições farmacêuticas e artigos farmacêuticos compreendendo tais composições, em que as composições compreendem múltiplas formas de dosagem, cada uma compreendendo um núcleo e um revestimento entérico, em que o núcleo compreende pelo menos um composto estimulando células enteroendócrinas a liberar pelo menos uma enterocina, em que o tamanho das formas de dosagem, em relação à maior dimensão das formas de dosagem, proporciona a entrada das formas de dosagem no intestino de um sujeito independente dos mecanismos de esvaziamento gástrico, e em que a composição compreende ainda um ou mais agentes gelificantes. A invenção também se refere ao tratamento e/ou prevenção de condições passíveis de estimulação da liberação de enterocina por células enteroendócrinas.
BR112022025220A 2020-06-10 2020-06-10 Composição farmacêutica e artigo farmacêutico BR112022025220A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/066149 WO2021249641A1 (en) 2020-06-10 2020-06-10 Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents

Publications (1)

Publication Number Publication Date
BR112022025220A2 true BR112022025220A2 (pt) 2023-03-07

Family

ID=71094332

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025220A BR112022025220A2 (pt) 2020-06-10 2020-06-10 Composição farmacêutica e artigo farmacêutico

Country Status (13)

Country Link
US (1) US20230233471A1 (pt)
EP (1) EP4164592A1 (pt)
JP (1) JP2023537461A (pt)
KR (1) KR20230040984A (pt)
CN (1) CN116096352A (pt)
AU (1) AU2020452539A1 (pt)
BR (1) BR112022025220A2 (pt)
CA (1) CA3182019A1 (pt)
CO (1) CO2022018623A2 (pt)
IL (1) IL298948A (pt)
MX (1) MX2022015645A (pt)
WO (1) WO2021249641A1 (pt)
ZA (1) ZA202213412B (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322697A (en) 1992-05-28 1994-06-21 Meyer James H Composition and method for inducing satiety
WO2010027498A2 (en) 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
US20140294951A1 (en) 2011-10-26 2014-10-02 Joseph M. Fayad Oral formulations mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
JP5226097B2 (ja) * 2011-03-30 2013-07-03 株式会社ファンケル サプリメントを内包する蓋体とサプリメント分散媒を充填したボトルからなるボトル入り飲料
PL2887925T3 (pl) * 2012-08-27 2017-07-31 Evonik Röhm Gmbh Odporna żołądkowo kompozycja farmaceutyczna lub nutraceutyczna z odpornością na wpływ etanolu
AU2015367634B2 (en) * 2014-12-15 2021-05-20 Teagasc - The Agriculture And Food Development Authority Gastro-resistant microencapsulates, and uses thereof to stimulate in-vivo ileal GLP-1 release in a mammal
WO2019170840A1 (en) * 2018-03-07 2019-09-12 Anabio Technologies Ltd. A composition for type ii diabetics and for use in providing sustained energy release over time

Also Published As

Publication number Publication date
IL298948A (en) 2023-02-01
CO2022018623A2 (es) 2023-03-07
CA3182019A1 (en) 2021-12-16
AU2020452539A1 (en) 2023-02-02
ZA202213412B (en) 2023-07-26
JP2023537461A (ja) 2023-09-01
US20230233471A1 (en) 2023-07-27
MX2022015645A (es) 2023-03-21
CN116096352A (zh) 2023-05-09
KR20230040984A (ko) 2023-03-23
WO2021249641A1 (en) 2021-12-16
EP4164592A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
BR112019000796A2 (pt) compostos e métodos para tratamento e prevenção da infecção flavivirus
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0510761A (pt) métodos de tratar um paciente afligido com pelo menos uma enfermidade e de reduzir ou eliminar rugas
BR112012025592A2 (pt) moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
BR112022018236A2 (pt) Compostos antivirais e métodos para a sua administração
BR112021019931A2 (pt) Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
PH12020550775A1 (en) Pentosan polysulfate and medicine containing pentosan polysulfate
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112018072201A2 (pt) composição compreendendo o componente à base de naftoquinona como ingrediente ativo, para prevenir ou melhorar a fadiga, cachexia, dor, declínio cognitivo e redução de células estaminais hematopoiéticas que são efeitos colaterais relacionados as drogas para tratamento anticancerígino
BR112022025220A2 (pt) Composição farmacêutica e artigo farmacêutico
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112020024261B8 (pt) Composto de fórmula (ia) e composição farmacêutica
BR112016029619A8 (pt) Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
BR112022007413A2 (pt) Métodos para estimular a produção de um ou mais ácidos graxos, para inibir o crescimento de um ou mais filos bacterianos, para promover a saúde gastrointestinal, o crescimento de um ou mais filos bacterianos, a integridade da barreira intestinal e um fenótipo intestinal e para tratar ou prevenir doença de parkinson
BR112022021166A2 (pt) Composto inovador [2-(dimetilamino)-2-fenilbutil]-3,4,5-trimetoxibenzoato 4-metil-2h-cromen-2-on-7-il sulfato e uso do mesmo
BR112018008835A2 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina